TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2667749
Drug: Metoclopramide (M)
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide (M) at 4 mg/kg combined with dexamethasone (D) at 40 mg
Study: 2667749
Drug: Metoclopramide (M)
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide (M) at 1, 2, and 4 mg/kg total dose
Study: 840119
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment with 3 weeks of bed rest for patients not suitable for early mobilisation
Study: 1568631
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g i.v. cefotaxime
Study: 1568631
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g amoxicillin plus clavulanic acid
Study: 4068610
Drug: Antacid (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid (group A)
Study: 4068610
Drug: H2 blocker
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H2 blocker (group B)
Study: 4068610
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (group A and B)
Study: 24387078
Drug: Tadalafil 5
Normalized name: tadalafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 5 mg once daily combined with sildenafil 50 mg as needed
Study: 16569261
Drug: Cefepime with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime with levofloxacin (C-L group, 20 patients)
Study: 16569261
Drug: Cefepime with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime with levofloxacin (C-L group)
Study: 3919604
Drug: Disodium Cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium Cromoglycate (DSCG) (5.2 mg 5 times daily)
Study: 29961573
Drug: Tocilizumab (IL-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (IL-6 receptor antagonist)
Study: 29374714
Drug: Thoracic radiotherapy
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic radiotherapy (TRT) of 45 Gy/30 fractions (twice daily)
Study: 29374714
Drug: Thoracic radiotherapy
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic radiotherapy (TRT) of 42 Gy/15 fractions (once daily)
Study: 23949963
Drug: Umeclidinium 62.5
Normalized name: UMECLIDINIUM 62.5MCG 7D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umeclidinium 62.5 μg
Study: 18797405
Drug: TMZ+training (TT),
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMZ+training (TT), n=30, received TMZ 20 mg three times daily for 8 weeks and underwent exercise training at 60% of oxygen uptake at peak, three times a week for 8 weeks.
Study: 18797405
Drug: TMZ (n=30),
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMZ (n=30), received TMZ 20 mg three times daily for 8 weeks without exercise training.
Study: 8430276
Drug: Duodenal perfusion
Normalized name: Sus scrofa duodenum preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duodenal perfusion with pancreaticobiliary juice at a rate of 5 ml/min for 10 min
Study: 8430276
Drug: Saline at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline at a rate of 5 ml/min for 10 min
Study: 31997509
Drug: 140 mg
Normalized name: caffeine 140 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 mg Livergol capsule per day for 30 days
Study: 31997509
Drug: Starch-containing capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starch-containing capsule as a placebo once a day for 30 days
Study: 27819257
Drug: Preemptive antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive antifungal therapy with voriconazole (initiating dose of 400 mg, then reduced to 200 mg every 12 hours)
Study: 27819257
Drug: Empirical antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical antifungal therapy with voriconazole (initiating dose of 400 mg, then reduced to 200 mg every 12 hours)
Study: 24304990
Drug: Insulin (group-A)
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin (group-A)
Study: 24304990
Drug: Metformin (group-B)
Normalized name: meningococcal group B vaccine
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (group-B)
Study: 19484982
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) by nasal spray
Study: 19484982
Drug: Nasal spray-inhaling
Normalized name: Allerest 12 Hour Nasal Spray Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray-inhaling combined administration
Study: 16887471
Drug: Intravenous metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous metronidazole 1500 mg day(‐1)
Study: 16887471
Drug: Intravenous metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous metronidazole 1000 mg day(‐1)
Study: 16887471
Drug: Intravenous metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous metronidazole 500 mg every 8 h
Study: 15646945
Drug: Manual brushing
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual brushing and daily flossing
Study: 11298072
Drug: Clinical pharmacy
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical pharmacy intervention involving development of professional relationships, nurse education on medication issues, and individualized medication reviews
Study: 2547139
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg piperazine oestrone sulphate/day
Study: 2547139
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg piperazine oestrone sulphate + 5.0 mg oestriol/day
Study: 2547139
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg oestradiol valerate/day
Study: 2547139
Drug: 10.0 mg
Normalized name: RUXOLITINIB 10.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.0 mg oestriol/day
Study: 2547139
Drug: Combination with
Normalized name: Iron in combination with folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination with levonorgestrel (LNG) 250 micrograms/day
Study: 14651947
Drug: Capsaicin injection
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin injection
Study: 19084439
Drug: Intravenous octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous octreotide 0.33 microg kg(‐1)h(‐1) infusion
Study: 12548313
Drug: Polyunsaturated spread
Normalized name: OMEGA-3 POLYUNSATURATES
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyunsaturated spread with 2 g of plant sterols
Study: 8296077
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg/day (n = 27)
Study: 8296077
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg/day (n = 29)
Study: 31267688
Drug: Nurse-administered intraocular
Normalized name: PAD,NURSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-administered intraocular injections
Study: 31267688
Drug: Physician-administered intraocular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician-administered intraocular injections
Study: 30372645
Drug: Etonogestrel (ENG)
Normalized name: Etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etonogestrel (ENG) contraceptive implant
Study: 30372645
Drug: 52 mg
Normalized name: papain 52 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 52 mg levonorgestrel-releasing intrauterine system (LNG-IUS)
Study: 18248651
Drug: Evening GH
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening GH and/or morning hydrocortisone treatment
Study: 18248651
Drug: Omission of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omission of evening GH and/or morning hydrocortisone treatment
Study: 18248651
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with GH
Study: 18248651
Drug: Omission of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omission of GH treatment
Study: 18248651
Drug: Omission of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omission of GH treatment in PHDC+ patients
Study: 18248651
Drug: Omission of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omission of GH treatment in patients with PHDC-
Study: 18248651
Drug: Treatment and
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment and meals omission
Study: 10473080
Drug: irinotecan (CPT‐11;
Approvals — FDA: no, EMA: no, PMDA: no
Description: irinotecan (CPT‐11; 200 mg/m2) as a 90‐min i.v. infusion followed by cisplatin (CDDP; 80 mg/m2) as a 3‐h i.v. infusion
Study: 28112575
Drug: International Warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: International Warfarin Pharmacogenetic Consortium algorithm
Study: 26100229
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m2, administered on day 1 every 21 days)
Study: 26100229
Drug: Volasertib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volasertib (300 mg, administered on day 1 every 21 days)
Study: 25146063
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training and music therapy
Study: 25146063
Drug: Pharmacotherapy (antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy (antidepressant drugs)
Study: 21148540
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of mononuclear bone marrow cells (n = 69)
Study: 21148540
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of mononuclear peripheral blood cells (n = 66)
Study: 21148540
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (n = 65)
Study: 19300145
Drug: High concentration
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High concentration botulinum toxin A (100 U/ml)
Study: 19300145
Drug: Low concentration
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low concentration botulinum toxin A (10 U/ml)
Study: 9133941
Drug: Nasal salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal salmon calcitonin 200 IU daily
Study: 3631942
Drug: Ciprofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (200 mg)
Study: 30817543
Drug: Alcohol (96%)
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol (96%) solution
Study: 30817543
Drug: Gentamicin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (80 mg) solution
Study: 30817543
Drug: Formalin solution
Normalized name: formalin
DrugBank: Formaldehyde (DB03843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Formalin solution
Study: 30817543
Drug: Saline (0.9%)
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (0.9%) solution
Study: 30817543
Drug: Cefazolin sodium
Normalized name: Cefazolin Sodium
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin sodium (Cezol 1gr) solution
Study: 29664109
Drug: Forced fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forced fluid removal (using furosemide and/or continuous renal replacement therapy)
Study: 21612045
Drug: Prophylactic measures
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic measures including oral cavity checkup, hygiene instruction, promotion of oral health, sealing of I permanent molar teeth
Study: 18755727
Drug: Midazolam (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (5-10 mg)
Study: 15926109
Drug: Canrenoate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canrenoate (400 mg)
Study: 15926109
Drug: Canrenoate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canrenoate (400 mg) + Aldosterone (3 microg/minute)
Study: 12576812
Drug: Neural network
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neural network algorithm based on urine levels of nuclear matrix protein‐22, monocyte chemoattractant protein‐1 and urinary intercellular adhesion molecule-1
Study: 1899350
Drug: misoprostol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: misoprostol (600 micrograms daily) with diclofenac (150 mg daily)
Study: 1899350
Drug: placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo with diclofenac (150 mg daily)
Study: 6347119
Drug: Low-dose fluphenazine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fluphenazine decanoate (1.25 to 5.0 mg/2 wk)
Study: 6347119
Drug: Standard-dose fluphenazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose fluphenazine decanoate (12.5 to 50.0 mg/2 wk)
Study: 6347119
Drug: Low-dose fluphenazine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fluphenazine decanoate
Study: 20558037
Drug: Composite score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite score from cardiovascular therapy trial
Study: 20558037
Drug: Binary composite
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Binary composite measure from cardiovascular therapy trial
Study: 15962224
Drug: 4-drug antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-drug antiretroviral regimen
Study: 12870834
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate dry powder inhaler (MF DPI) 400 microg twice daily
Study: 12870834
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate dry powder inhaler (MF DPI) 800 microg twice daily
Study: 1714697
Drug: Cow's milk
Normalized name: Cow's milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cow's milk infant formula with 40 mg Fe/100 g
Study: 1714697
Drug: Cow's milk
Normalized name: Cow's milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cow's milk infant formula with 8.3 mg Fe/100 g
Study: 26743348
Drug: Atorvastatin reload
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin reload (AR) 80 mg 12 hours before + 40 mg 2 hours before PCI
Study: 26743348
Drug: Atorvastatin reload
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin reload (AR)
Study: 20558006
Drug: Prednisolone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (5 mg and 10 mg)
Study: 18089905
Drug: Caffeinated drink
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeinated drink (5 mg/kg)
Study: 8648202
Drug: ca A/Los
Approvals — FDA: no, EMA: no, PMDA: no
Description: ca A/Los Angeles/2/87 (H3N2) vaccine
Study: 8648202
Drug: bivalent ca
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: bivalent ca vaccine
Study: 8648202
Drug: monovalent ca
Normalized name: CA-170
DrugBank: CA-170 (DB15772)
Approvals — FDA: no, EMA: no, PMDA: no
Description: monovalent ca H1N1 vaccine
Study: 26666688
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy‐guided self‐help manual
Study: 22417778
Drug: Bacteroides xylanisolvens
Normalized name: Bacteroides thetaiotaomicron
DrugBank: Bacteroides thetaiotaomicron (DB17879)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacteroides xylanisolvens DSM 23964 (10^12 cells) in spray-dried fermented milk for 6 weeks
Study: 15024563
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml (15 mg) 0.5% hyperbaric bupivacaine (bilateral group)
Study: 15024563
Drug: 1.5 ml
Normalized name: Humulin 70/30 1.5 ML Pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 ml (7.5 mg) 0.5% hyperbaric bupivacaine (unilateral group)
Study: 12350190
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care program (n = 447)
Study: 2511696
Drug: pentaerythrityltetranitrate (PETN)
Normalized name: Pentaerythritol tetranitrate
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pentaerythrityltetranitrate (PETN) 50-300 mg
Study: 2511696
Drug: isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: isosorbide dinitrate (ISDN) 40-120 mg
Study: 2511696
Drug: sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual nitroglycerin
Study: 981634
Drug: Large daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large daily fractions of 400 rads/day for 10-12 treatments
Study: 11551733
Drug: Delayed-treatment control
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-treatment control (DTC)
Study: 9704701
Drug: Prolonged heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged heparin infusion after PTCA
Study: 9704701
Drug: No postprocedure
Approvals — FDA: no, EMA: no, PMDA: no
Description: No postprocedure heparin (control group)
Study: 25491493
Drug: Eluxadoline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eluxadoline (200 mg dose) coadministered with cyclosporine
Study: 25491493
Drug: Eluxadoline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eluxadoline (200 mg dose) coadministered with probenecid
Study: 20798655
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of calcium 20 min before exercise
Study: 20798655
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of calcium every 15 min during exercise (1000 mg total)
Study: 12956861
Drug: Intravenous immunoglobulins
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulins (IgG) at doses of 1, 5, and 10 mg/ml
Study: 2707117
Drug: 28 g
Normalized name: SM Syringe 28 g, 0.5cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 g sucrose during a mixed meal (meal A)
Study: 25293368
Drug: AS03B-adjuvanted H5N1
Normalized name: Influenza A monovalent (H5N1), ADJUVANTED-2013
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03B-adjuvanted H5N1 influenza vaccine (1.9 µg of hemagglutinin and 5.93 mg of α-tocopherol)
Study: 25293368
Drug: AS03B-adjuvanted H5N1
Normalized name: Influenza A monovalent (H5N1), ADJUVANTED-2013
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03B-adjuvanted H5N1 influenza vaccine
Study: 21730902
Drug: Premature Infant
Normalized name: Premature infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premature Infant Oral Motor Intervention (PIOMI) for 5 minutes per day for 7 consecutive days
Study: 9282969
Drug: Cholestyramine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine (6 g/h)
Study: 8332150
Drug: Other antiarrhythmic
Normalized name: Other antiarrhythmics, class I and III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antiarrhythmic drugs combined
Study: 26983642
Drug: Oral PSORI-CM01
Normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral PSORI-CM01 plus topical sequential therapy
Study: 26983642
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus topical sequential therapy
Study: 26983642
Drug: Oral PSORI-CM01
Normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral PSORI-CM01
Study: 17892610
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine (0.5%) + ketamine (0.1 mg kg‐1)
Study: 17892610
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine (0.5%) + ketamine (0.1 mg kg‐1) + midazolam (0.02 mg kg‐1)
Study: 12364444
Drug: Canrenoate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canrenoate (200 mg as an iv bolus, followed by 200 mg infused in 250 ml saline)
Study: 12364444
Drug: Alprazolam (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.02 mg/kg, orally)
Study: 10469814
Drug: Amethocaine gel
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amethocaine gel (1 g for 30 minutes)
Study: 10469814
Drug: Lidocaine-prilocaine cream
Normalized name: lidocaine / prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine-prilocaine cream (1 g for 60 minutes)
Study: 1808626
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg aspirin daily
Study: 1808626
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg aspirin daily
Study: 6351586
Drug: Chromium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chromium supplementation (200 micrograms trivalent chromium daily for 6 weeks)
Study: 23401275
Drug: Azithromycin combined
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin combined with prednisolone (treatment group, n = 28)
Study: 19388505
Drug: Preoperative fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative fluid bolus (up to 1,000 mL using the 4‐2‐1 formula)
Study: 11167354
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy plus training on the use of nasal spray (Group B)
Study: 11167354
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy plus training on the use of nasal spray and a lesson on rhinitis and asthma (Group C)
Study: 11167354
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy alone (Group A)
Study: 9554567
Drug: rhIGF‐1 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF‐1 (80 µg/kg/day)